Patient's Satisfaction Clinical Trial
Official title:
Prospective Questionnaire Based Observational Study Measuring the Degree of Patient's Satisfaction With the Outcomes of Expensive Cytotoxic Agents.
The purpose of this study is to determine whether there is positive (beneficial) impact of expensive cytotoxic agents on the cancer patients. It is a questionnaire based study that will be filled by the cancer patients without obligations.
This is a prospective observational questionnaire based study measuring the degree of
patient satisfaction with the outcomes of some expensive cytotoxic agents.
The tested drugs are trastuzumab, lapatinib, sunitinib, m tor inhibitors, sorafenib,
cetuximab, panitumumab, bevacizumab, erlotinib, rituximab, imatinib mesylate, gefitinib,
abiraterone acetate, cabazitaxel, pertuzumab, fulvestrant, pemetrexate and crizotinib.
The evaluation will be through a predesigned template questionnaire that will be applied to
all the tested drugs. The questions are divided into five categories measuring five items,
the negative impact of the drug on patient's finances, satisfaction with drug efficacy,
toxicity and effect on quality of life, satisfaction with drug availability in the market
and satisfaction with the received education from the treating physician about the drug
before usage. A predesigned questionnaire based scoring system will categorizes the
processed data to low, intermediate and high score for each of the five measured topics. The
data will be processed and each drug will acquire low, moderate or high score. Subsequent
recommendations for revision of the drug price, cost effective analysis studies, physician
education about drug pharmaceutical perspectives will be elaborated for some drugs. The
study will clarify the most annoying and frequently reported side effect for each drug and
will suggest recommendations for its treatment.
The study is currently recruiting patients.
The study is currently accepting to add authors (Oncology physicians) who can fulfill the
following prerequisites:
1. Answer a questionnaire that will be mailed to him upon request and propagate this
questionnaire to 10 oncology physicians in his center to answer them. (The 11
questionnaires should be scanned and mailed to ellithym@med.asu.edu.eg. or given as
hard copies to Dr Mahmoud Ellithy (Mobile: +01000069694).
(This questionnaire is designed to be answered by oncology physicians to measure their
degree of satisfaction with the outcomes of expensive cytotoxic agents).
The questionnaire can be answered electronically online
https://www.surveymonkey.com/r/Cureandmore. (for oncologist with foreign nationality
who want to share as an author. Egyptian oncologists should fill a hard copy not
online).
Disclosure: The Questionnaire for the physicians is a clinical trial registered
clinical trials.gov with NCT02630979. URL.
https://clinicaltrials.gov/ct2/show/nct02630979.
2. Each author must share with at least 90 patients with at least 5 patients for each
drug. The maximum allowed numbers of authors from each center are two authors sharing
with 180 patients till closure of the study in 30th January 2019.
3. Share with any new idea that will add benefit to the study. ( Item 1 and 2 are
mandatory).
The Oncologist who want to share as an author in this study must sign a memorandum of
aggrement consenting for the accuracy, confidentiality and validity of the data with a
copyright, stating that he must obtain a written permission from the research team (Cure and
More research team) to produce any text, figures, tables or illustrations from this study in
future works of his own.
;
Observational Model: Ecologic or Community, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05703048 -
The Effect of Esmolol Versus Dexmedetomidine on Postoperative Pain Control in Endoscopic Sinus Surgery: A Randomized Trial
|
N/A |